DexCom

Q2 FY2026 EarningsQ2 FY2026 results significantly beat consensus across all key metrics: revenue reached $1.308B (+1.39% vs. expected), while non-GAAP EPS of $0.70 comfortably exceeded the $0.61 mean estimate. The performance was driven by a robust 19% YoY growth in international markets and a substantial 590 bps expansion in non-GAAP operating margin to 25.1%. Management subsequently raised FY26 revenue and margin guidance, signaling strong continued demand for CGM technology.